Skip to main content
Log in

Terlipressin for Type 1 Hepatorenal Syndrome

  • Correspondence
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Terbah R, Chapman B, Gow P, Sinclair M, Angus P, Testro A. The efficacy, safety, and tolerability of outpatient continuous terlipressin infusion in patients awaiting liver transplantation. J Gastroenterol Hepatol. 2019;34:105.

    Google Scholar 

  2. Vasudevan A, Ardalan Z, Gow P, Angus P, Testro A. Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome. Hepatology. 2016;64:316–318.

    Article  Google Scholar 

  3. Chapman B, Gow P, Angus P, Sinclair M, Testro A. Outpatient terlipressin infusion increases dietary intake and functional muscle strength in patients awaiting liver transplant. J Hepatol. 2018;68:S726.

    Article  Google Scholar 

  4. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64:531–537.

    Article  CAS  Google Scholar 

  5. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983–992.

    Article  CAS  Google Scholar 

  6. Neri S, Pulvirenti D, Malaguarnera M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830–835. https://doi.org/10.1007/S10620-007-9919-9.

    Article  CAS  PubMed  Google Scholar 

  7. Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150:1579–1589.e1572.

    Article  CAS  Google Scholar 

  8. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.

    Article  Google Scholar 

  9. Late-Breaking Abstracts—Presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting™ 2019. Hepatology. 2019;70:1477a–1501a.

  10. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Testro.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Terbah, R., Gow, P., Sinclair, M. et al. Terlipressin for Type 1 Hepatorenal Syndrome. Dig Dis Sci 65, 2454–2455 (2020). https://doi.org/10.1007/s10620-020-06370-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-020-06370-8

Navigation